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Introduction: The serotonin (5-HT) syndrome (SS) in man covers side effects of drugs in over dose that in-
crease synaptic 5-HT concentration or directly activate 5-HT receptors. The SS is characterized by mental state
alterations, neuromuscular excitation, and autonomic dysregulation. In mice, a set of behavioral and autonomic
responses can be induced by the same serotonergic drugs as in man. The role of the 5-HT1A receptor for the mu-
rine SS has been extensively studied and several responses have been attributed to 5-HT1A receptor activation. So
far, 5-HT2A receptor activation is thought to induce head twitches and hypothermia. The aim of this study is to
deﬁne the impact of the 5-HT2A and the 5-HT1A receptor for different SS-like responses. Methods: The effects
of the full 5-HT1A receptor agonist 8-OH-DPAT, the partial 5-HT1A agonist buspirone, and the 5-HT2A receptor ag-
onist TCB-2were investigated inmale NMRImice. The responseswere compared with the effects induced by the
5-HT precursor 5-HTP. Results: Flat body posture, hindlimb abduction, Straub tail, tremor, piloerection and de-
creased rearing were observed after 8-OH-DPAT treatment. A similar set of responses was seen after administra-
tion of buspirone. However, the Straub tail response did not occur, probably due to the lower efﬁcacy of
buspirone at postsynaptic 5-HT1A receptors. As expected, TCB-2 induced head twitches, but also evoked ﬂat
body posture, hindlimb abduction, and piloerection, and decreased the numbers of rearings and defecation
boli. Discussion: The Straub tail response seems to be a speciﬁc sign for postsynaptic 5-HT1A receptor activation.
In addition, the 5-HT2A receptor has more impact on the 5-HT syndrome than previously suggested. By inducing
the broadest spectrumof signs, 5-HTP seems to be suitable as a positive controlwhen investigating the 5-HT syn-
drome inmice. In summary, the murine model of the SS is a valid tool for preclinical studies to screen drugs and
drug combinations for the risk to cause an SS in man.
©2014 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Serotonin (5-HT) is a key neurotransmitter and is involved in the
therapeutic action of antidepressants, anxiolytics, and atypical antipsy-
chotics. Most serotonergic drugs used for treatment of mental illness
enhance the activity of the serotonergic transmission system or act as
agonists at 5-HT receptors. Unwanted effects of serotonergic drugs in
patients result from toxic actions in over-dose and manifest clinically
in characteristic symptoms, leading to the diagnosis of a serotonin syn-
drome (SS). The SS is a potentially life-threatening toxidrome (Boyer &L-tryptophan; 8-OH-DPAT, 8-
SS, serotonin syndrome; SRI,
reuptake inhibitor; TCB-2, 4-
e hydrobromide.
ogy and Toxicology, Dept. of
se 20, 14195 Berlin, Germany.
. This is an open access article underShannon, 2005) and has been observed most frequently after ingestion
of a monoamine oxidase inhibitor together with another serotonin en-
hancing drug, e.g. selective 5-HT reuptake inhibitors (SSRI) (Gillman,
2005; Isbister & Buckley, 2005). Several other drugs have been associat-
ed with the induction of an SS, e.g. mood stabilizers, opioid analgesics,
and illicit drugs (see Boyer & Shannon, 2005; Sun-Edelstein, Tepper, &
Shapiro, 2008).
Few of the various 5-HT receptor types and subtypes have been im-
plicated in the SS. The 5-HT2A receptor subtype was suggested to medi-
ate hyperthermia in man (Isbister & Buckley, 2005), which occurs in
severe cases of the SS (Dunkley, Isbister, Sibbritt, Dawson, & Whyte,
2003; Neuvonen, Pohjola-Sintonen, Tacke, & Vuori, 1993) and which
is associated with high mortality (Boyer & Shannon, 2005; Nisijima,
Yoshino, & Ishiguro, 2000). The recommendation for the treatment
of moderate to severe cases of the SS includes the administration of
5-HT2A antagonists, e.g. cyproheptadine (Boyer & Shannon, 2005;
Gillman, 1999).
Attention has also been drawn to the 5-HT1 receptor family, since
induction of an SS has been reported during concurrent therapythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tial 5-HT1A receptor agonist buspirone in combination with an SSRI
contributes to an SS (Goldberg & Huk, 1992; Manos, 2000; Parks
et al., 2012).
As several novel psychoactive drugs possess 5-HT1A agonist prop-
erties, more cases of SS are expected in the future (de Paulis, 2007;
Maurel et al., 2007; Zajdel et al., 2007). For example, the antidepres-
sant vilazodone exerts dual action, being an SSRI as well as a 5-HT1A
receptor agonist. The manufacturer of vilazodone reported a poten-
tially life-threatening SS by this drug alone or by concomitant inges-
tion of other serotonergic or 5-HT enhancing drugs (see prescribing
information of Viibryd®). The atypical neuroleptic aripiprazole, a
partial D2 and partial 5-HT1A agonist as well as a 5-HT2A antagonist,
has already been associated with an SS, too (Primeau, Pomeraniec,
& Wallace, 2012).
Therefore, there is a high need for preclinical tests to screen drugs
and drug combinations for the risk to cause an SS in patients. There
are several versions of animal models for the SS in literature, which
can be used in translational research. The versions differ mostly regard-
ing their spectrum of assessed responses, which might be based on di-
verging opinions on the relevance of responses (Haberzettl, Bert, Fink,
& Fox, 2013).
Drugs that induce the SS in humans likewise elicit characteristic
responses in rodents. As known for the symptoms of the SS in man,
the responses in the laboratory rodents can also be categorized in
neuromuscular and vegetative signs (Kalueff, LaPorte, & Murphy,
2008; Stewart et al., 2013). In rodents and zebraﬁsh, the expression
of the signs of the SS has been shown to be positively correlated with
the brain 5-HT levels (Stewart et al., 2013). Amongst rodents, rats
have been extensively used for investigating the SS. In literature,
four-times more reports exist describing the SS in rats in compari-
son to mice. However, with the ever increasing number of genetical-
ly manipulatedmice there is a need for better characterization of the
SS in this species. In particular, little is known concerning the role of
distinct 5-HT receptors for SS-like responses in mice (see Haberzettl
et al., 2013).
5-HT1A receptor activation is thought to contribute mainly to the SS
in mice. Several SS-like behaviors, as backward walking, ﬂat body pos-
ture, forepaw treading, head weaving, hindlimb abduction, Straub tail,
and tremor as well as the autonomous response hypothermia have
been demonstrated following administration of 5-HT1A receptor ago-
nists (Bert et al., 2006; Blanchard et al., 1997; Fox, Jensen, Gallagher, &
Murphy, 2007; Yamada, Sugimoto, & Horisaka, 1988).
The 5-HT2A receptor is predominantly known for mediation of
head twitches in mice and induction of hypothermia (Corne &
Pickering, 1967; Corne, Pickering, & Warner, 1963; Fox, French,
LaPorte, Blackler, & Murphy, 2010). However, various authors con-
sider head twitches in mice as a separate entity and solely use this
sign as a tool for studying function of 5-HT2A receptor activity (e.g.
Van Oekelen, Megens, Meert, Luyten, & Leysen, 2002). Other authors
regard head twitches as a component of the animal model of the SS
(e.g. Darmani, Martin, Pandey, & Glennon, 1990; Isbister & Buckley,
2005; Peroutka, Lebovitz, & Snyder, 1981). Besides that, the role of
the 5-HT2A receptor for the meditation of further responses of the
murine SS is not clear.
The aim of the present study was to determine and to differentiate
the impact of the 5-HT1A and the 5-HT2A receptor for behavioral SS re-
sponses. To that end, the effects of the full 5-HT1A agonist 8-OH-DPAT
and the partial 5-HT1A agonist buspirone as well as the 5-HT2A receptor
agonist TCB-2 were investigated. To meet a standard for SS-like re-
sponses induced by increased 5-HT levels, the effects of 5-HTP (80,
160, and 320 mg/kg) as previously published (Haberzettl, Fink, & Bert,
2014) were compared with the present effects of the agonists at the
5-HT1A and the 5-HT2A receptor. The understanding of the role of the
5-HT1A and the 5-HT2A receptor is a precondition to evaluate the predic-
tive validity of the SS-like responses in mice. A validated animal modelis needed to improve the translational approach to predict the risk of
SS by novel complex acting drugs and drug combinations.
2. Material and methods
2.1. Animals
Male NMRI mice (HsdWin: NMRI) aged 10 weeks were used in all
experiments. The mice (n = 12–14 per group), obtained from Harlan–
Winkelmann (Horst, Netherlands), were habituated in the animal
facilities for at least two to three weeks prior to the experiments. The
mice were pair-housed under standardized conditions (23 ± 2 °C
room temperature, 50 ± 5% humidity) with an artiﬁcial 12/12 h light/
dark cycle (lights on 06.00–18.00 h, illumination strength ca. 250 lx).
Food (Altromin 1326, Lage, Germany) and tap water were available ad
libitum. Experiments were performed according to the guidelines of
the German Animal Protection Law and were approved by the Berlin
State Authority (“Landesamt für Gesundheit und Soziales”).
2.2. Drug treatment
8-OH-DPAT ((±)-8-hydroxy-N,N-dipropyl-2-aminotetralin
hydrobromide) was obtained from Sigma-Aldrich Chemie GmbH,
Schnelldorf, Germany. Buspirone (N-[4-[4-(2-Pyrimidinyl)-1-
piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride)
was obtained from the European Directorate for the Quality of Medi-
cines & HealthCare (EDQM), Strasbourg, France. TCB-2 (4-bromo-3,6-
dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide) was
obtained from Tocris Bioscience, Bristol, United Kingdom.
8-OH-DPAT, buspirone (both: 0.5, 1, 2, 4 mg/kg) and TCB-2
(2.5, 5 mg/kg) were freshly dissolved in 0.9% saline. The dose range
was based on previous studies (Bert et al., 2006; Fox et al., 2010;
Smith & Peroutka, 1986).
One vehicle group was used for each drug across the range of doses,
since no signiﬁcant differences were observed between the animals of
each drug vehicle group. All drugs andvehiclewere injected intraperito-
neally (i.p.) in a volume of 10 ml/kg body weight.
2.3. Behavioral experiments
The mice were transferred in their home cages with free access to
food and tap water to the experimental room the day before the exper-
iment. From 08.00 to 12.00 h on the following day, the experiments
were carried out in a sound attenuated chamber. Immediately after
drug/vehicle injection, the mice were placed singly in the center of a
black painted Makrolon type II cage (260 × 200 × 140mm) and the be-
havior was monitored by an observer blind to drug treatment for a
period of 90 min. Between each trial, the cages were cleaned with a so-
lution of water and detergent. Four mice were tested at the same time.
Beginning 5 min post-injection, the occurrence of the following SS-
like responses was assessed every 5 min for 1 min by instantaneous
sampling and was rated as present (=1) or absent (=0):
• Flat body posture (the greater ventral part of the body is in contact with
the cage ﬂoor and the animal moves similar to a reptile. To our experi-
ence ﬂat body posture is often accompanied by hindlimb abduction)
• Head weaving (repetitive movement of the head from side to side, like
watching a tennis match)
• Hindlimb abduction (both hindlimbs are splaying out to the side. Toes
of the distal limb are also often splayed out.)
• Tremor (shivering encompassing the whole body at rest)
• Straub tail (a rigid dorsiﬂexed tail in a sharper angle at the base of
the tail)
• Backward walking (the animal continuously moves backwards for
some cm)
• Hunched back (dorsal arching of the spine relative to a line between
Table 2
Effects of TCB-2 on SS-like responses in mice.
Responses Treatment
Vehicle TCB-2 p value
2.5 mg/kg 5 mg/kg
Sum scores of
Flat body posture 0.1 ± 0.1 1.1 ± 0.6 2.4 ± 0.8 b0.001
Hindlimb abduction 0.1 ± 0.1 6.9 ± 0.8 8.3 ± 0.9 b0.001
Piloerection 0.6 ± 0.2 7.0 ± 1.2 6.4 ± 1.2 b0.001
Head twitches 0.0 ± 0.0 10.2 ± 0.5 10.1 ± 0.5 b0.001
Rearing [n] 55.3 ± 5.5 33.2 ± 4.6 25.5 ± 3.7 b0.001
Defecation boli [n] 10.8 ± 1.6 8.2 ± 1.0 3.8 ± 0.6 0.001
Shown are the means ± SEM of the sum scores of the 12 assessment points for each ani-
mal and each response. P values for treatment effectswere calculated by one-wayANOVAs
for each drug and response. Dose response effects were analyzed by Dunnett's tests versus
vehicle indicated as bold numbers. ns = not signiﬁcant.
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• Piloerection (erected body hair, most prominent in the region of
the neck)
• Head shakes (short and ﬁrm movement of the head in any direction
comparable to the Pinna reﬂex reaction)
• Forepaw treading (the animal is at rest andmoves the forepaws alter-
nating and repetitively)
• Head twitches (jerky movements of the head only towards the neck).
Additionally, as a measure for vertical activity the number of
rearings (i.e. both forepaws lifted of the cage ﬂoor) was counted every
5min for 1min. 90min after drug administration, the occurrence of sal-
ivationwas rated as present (=1) or not-present (=0) and the number
of defecation boli was counted.
2.4. Statistical analysis
Since no signiﬁcant behavioral changes were detected in the last
30 min of the observation time, we only analyzed the data of the ﬁrst
60 min (0–60 min), resulting in 12 assessment points. For a clearer
overview, we omitted the aspect of time and summed up the scores
measured by instantaneous sampling (i.e. 0 or 1) for eachmouse and re-
sponse resulting in a possible maximum value of 12. The number of
rearings was also summed up over the 12 assessment points. For all
treatment groups, themeans±SEMof the sum scores for each response
were calculated as shown in Tables 1 and 2. In order to detect dose re-
sponse effects, the datawere analyzed using one-way ANOVAs followed
by post hoc Dunnett's tests in comparison to vehicle. A probability value
of 0.05 was considered to be statistically signiﬁcant. In the Tables, only
those SS responses are shown where signiﬁcant differences were
detected. For salivation, only descriptive statistic was conducted.
3. Results
3.1. Effects of 8-OH-DPAT and buspirone
8-OH-PAT induced some SS-like responses (see Table 1). Based on
Dunnett's post hoc analyses, the high doses (2 and 4 mg/kg) of 8-OH-
DPAT signiﬁcantly increased the occurrence of ﬂat body posture
(2 and 4 mg/kg: p = 0.016 and p b 0.001, respectively), hindlimb ab-
duction (both: p b 0.001), piloerection (both: p b 0.001), the Straub tail
(both: p b 0.001) and tremor (p = 0.019 and p b 0.001, respectively),
compared to vehicle. The two lower doses (0.5 and 1 mg/kg) of 8-OH-
DPAT both increased hindlimb abduction (both: p b 0.001) and
piloerection (both: p b 0.001). Additionally, 1 mg/kg 8-OH-DPAT in-
duced the Straub tail (p b 0.001) and tremor (p b 0.001). Across
the range of doses, only 1 and 4 mg/kg 8-OH-DPAT decreased rearings
(1 and 4 mg/kg: p = 0.030 and p b 0.001, respectively).
In comparison to 8-OH-DPAT, buspirone produced fewer SS-like re-
sponses (see Table 2). The higher doses (2 and 4 mg/kg) of buspirone
signiﬁcantly increased the occurrence of ﬂat body posture (both:Table 1
Effects of 8-OH-DPAT and buspirone on SS-like responses in mice.
Responses Treatment
Vehicle 8-OH-DPAT
0.5 mg/kg
1 mg/kg 2 mg/kg 4 mg/
Sum scores of
Flat body posture 0.0 ± 0.0 2.2 ± 0.9 2.9 ± 0.9 3.6 ± 1.0 7.2 ±
Hindlimb abduction 0.2 ± 0.2 7.8 ± 1.0 9.5 ± 0.9 10.3 ± 0.8 12.0 ±
Piloerection 0.8 ± 0.4 9.0 ± 1.3 10.29 ± 0.8 11.2 ± 0.5 11.9 ±
Tremor 0.0 ± 0.0 2.2 ± 0.7 3.1 ± 0.6 3.2 ± 0.9 8.2 ±
Straub tail 0.0 ± 0.0 1.7 ± 0.7 5.1 ± 0.8 6.7 ± 1.0 5.4 ±
Rearing [n] 60.0 ± 4.9 48.3 ± 7.1 35.6 ± 6.3 40.1 ± 8.0 13.4 ±
Shown are themeans ± SEMof the sum scores of the 12 assessment points for each animal and
drug and response. Dose response effects were analyzed by Dunnett's tests versus vehicle indip b 0.001), hindlimb abduction (both: p b 0.001), piloerection (both:
p b 0.001) and tremor (both: p b 0.001), compared to vehicle. The
lower doses (0.5 and 1 mg/kg) of buspirone increased hindlimb abduc-
tion (both: p b 0.001) and piloerection (both: p b 0.001), and 1 mg/kg
buspirone induced additionally ﬂat body posture (p= 0.001). Moreover,
1, 2, and 4 mg/kg buspirone decreased the number of rearings (1 mg/kg:
p= 0.031; 2 and 4 mg/kg: both: p b 0.001). In all tested doses, buspirone
in did not induce the Straub tail response.
After the administration of 8-OH-DPAT or buspirone, no signiﬁcant
changes were found for backward walking, forepaw treading, head
twitches and weaving, hunched back, and defecation.
3.2. Effects of TCB-2
As expected, TCB-2 induced in both doses (2.5 and 5.0 mg/kg) head
twitches in NMRImice (for both: p b 0.001 after Dunett's post hoc analy-
sis). In addition, 2.5 and5 mg/kg TCB-2 lead to the occurrence of hindlimb
abduction (both: p b 0.001), piloerection (both: p b 0.001) and to a
decrease in the number of rearings (2.5 and 5.0 mg/kg: p = 0.005 and
p b 0.001, respectively), Moreover, the high dose of TCB-2 induced ﬂat
body posture (p = 0.009) and decreased the number of defecation boli
(p b 0.001).
TCB-2 in both doses did not provoke backward walking, forepaw
treading, head weaving, hunched back, Straub tail, and tremor.
4. Discussion
The current study was aimed at determining the role of the 5-HT1A
and the 5-HT2A receptor for behavioral SS-like responses inmice. Before
applying the animal model of the SS in drug screening, it is necessary to
ﬁnd out which 5-HT receptor types and subtypes are responsible for the
induction of the responses. There is evidence that 5-HT1A and 5-HT2A re-
ceptors aremainly involved in the SS in rodents (Haberzettl et al., 2013).
However, it is not clear to which extent and proportion both receptorskg p value Buspirone
0.5 mg/kg
1 mg/kg 2 mg/kg 4 mg/kg p value
0.9 b0.001 1.0 ± 0.5 4.1 ± 0.9 5.4 ± 0.8 7.7 ± 0.9 b0.001
0.0 b0.001 5.7 ± 1.1 10.6 ± 0.7 11.2 ± 0.5 11.6 ± 0.4 b0.001
0.1 b0.001 9.6 ± 1.0 11.9 ± 0.2 11.7 ± 0.2 12.0 ± 0.0 b0.001
1.1 b0.001 2.2 ± 0.8 2.3 ± 0.7 9.2 ± 0.8 9.8 ± 1.0 b0.001
1.0 b0.001 0.0 ± 0.0 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 ns
3.8 b0.001 52.7 ± 5.1 42.9 ± 4.3 30.8 ± 3.2 21.8 ± 4.4 b0.001
each response. P values for treatment effectswere calculated by one-wayANOVAs for each
cated as bold numbers. ns = not signiﬁcant.
Table 3
Overview of the SS-like responses induced by 4 mg/kg 8-OH-DPAT, 4 mg/kg buspirone,
5 mg/kg TCB-2, and 160 mg/kg 5-HTPa in mice.
Response 8–OH–DPAT Buspirone TCB–2 5–HTP
Flat body posture
Hindlimb abduction
Piloerection
Tremor
Head twitches
Straub tail
Hunched back
Forepaw treading
Decrease in rearing
Changes in defecation
a See Haberzettl et al., 2014.
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ic responses exist. In order to estimate the functional relevance of par-
ticular 5-HT receptors, the results have to be compared to a 5-HT
enhancing drug that elicits the whole spectrum of SS-like responses.
For this purpose, the responses induced by 5-HTP that we recently
reported (Haberzettl et al., 2014) are included in the discussion. In
our previous publication, we tested the effects of 5-HTP according
to the experiments in the present study. We found that 5-HTP in
doses of 160 and 320 mg/kg induced a broad spectrum of SS-like re-
sponses in mice, including ﬂat body posture, hindlimb abduction,
piloerection, tremor, forepaw treading, head twitches, hundched back,
and a decrease of rearings (Haberzettl et al., 2014). Compared to the
two other 5-HT enhancing drugs (i.e. ﬂuoxetine and tranylcypromine),
5-HTP seemed to produce a more severe SS in mice (Haberzettl et al.,
2014).
In our study, most of the observed effects induced by 8-OH-DPAT
generally coincide with results of previous studies conducted in mice
(Bert et al., 2006; Blanchard et al., 1997; Fox et al., 2007; Izumi et al.,
2006; Yamada et al., 1988). In line with these studies, we registered
ﬂat body posture, hindlimb abduction, Straub tail, tremor, and de-
creased rearing in NMRI mice after the administration of 8-OH-DPAT.
In contrast to other studies (Haberzettl et al., 2013), forepaw treading,
backward walking, and headweaves were not seen in our experiments.
However, we could demonstrate that piloerection was reliably induced
by 8-OH-DPAT treatment. Piloerection as a SS-like response has not
been frequently reported in literature (Diaz & Maroteaux, 2011;
Hwang & Van Woert, 1979) and has not been observed following the
administration of 5-HT1A receptor agonists until now. When discussing
analogy and variation of our results to literature, strain differences have
to be taken into account. However, our results conﬁrm themajor role of
the 5-HT1A receptor in the murine SS. To our knowledge, a behavioral
analysis following the administration of the partial 5-HT1A agonist
buspirone has not been performed in mice until now. It was merely
shown that buspirone decreases the number of rearings (Cole &
Rodgers, 1994). In our study, the partial agonist buspironewas as effec-
tive as 8-OH-DPAT in triggeringmost responses of the SS. The difference
in the responses induced by both agonists is that 8-OH-DPAT produced
the Straub tail response, whereas buspirone did not.
The Straub tail response was formerly also known as spontaneous
tail ﬂick response and was evoked in rats by systemic administration
of 5-HT1A agonists with high efﬁcacy as well as by releasers of 5-HT
but not by the partial agonists, buspirone and ipsapirone (Millan,
Bervoets, & Colpaert, 1991). The Straub tail response elicited by 8-OH-
DPAT is assumed to be induced at postsynaptic 5-HT1A receptors local-
ized in the lumbar spinal cord (Bagdy & To, 1997; Bervoets, Rivet, &
Millan, 1993). Buspirone is a partial agonist with a markedly lower efﬁ-
cacy than 8-OH-DPAT regarding postsynaptic mediated 5-HT1A effects
(Celada, Bortolozzi, & Artigas, 2013; Middlemiss & Tricklebank, 1992;
Millan et al., 1992). Taken together, these facts and the results of our
study indicate that in mice and rats the Straub tail response is mainly
mediated by postsynaptic 5-HT1A receptors and, hence, can be regarded
as a speciﬁc answer to activation of this 5-HT receptor subtype in mice
as well as in rats. 5-HT1A receptor agonists that fail to induce the Straub
tail response have seemingly a lower efﬁcacy at postsynaptic 5-HT1A re-
ceptor sites.
(Fox et al., 2010) reported that the 5-HT2A agonist, TCB-2, produced
head twitches inmice and induced hypothermia but had no effect on lo-
comotion. As expected, TCB-2 also induced head twitches in our exper-
iment. The mediation of the head twitches in mice by 5-HT2A receptors
has been known since the '80s (Hoyer, Hannon, & Martin, 2002; Van
Oekelen et al., 2002) and this sign has been used to assess drug effects
at the 5-HT2A receptor. We have recently demonstrated that 5-HTP
also induces head twitches in mice (see Table 3 and Haberzettl et al.,
2014). This observation together with the ﬁnding gained by the admin-
istration of TCB-2, strongly argues for the head twitch response as a
component of the murine SS. Hence, we suggest that this sign shouldbe included when the SS is studied in mice. In the present study we
could clearly demonstrate that TCB-2 additionally induced ﬂat body
posture, hindlimb abduction, and piloerection, and also decreased the
numbers of rearings and of defecation boli. To our knowledge, this is
the ﬁrst time that a 5-HT2A receptor agonist was demonstrated to in-
duce such a broad spectrum of behavioral responses in mice. Evidence
for a role of the 5-HT2A receptor in other behavioral components of the
SS than head twitches had only been derived from studies in rats (e.g.
Backus, Sharp, & Grahame-Smith, 1990; Cowen, Grahame-Smith, Green,
& Heal, 1982; Green, Hall, & Rees, 1981; Nimgaonkar et al., 1983;
Pranzatelli & Pluchino, 1991). Our results suggest that the 5-HT2A receptor
is involved in more SS-like responses in mice than previously assumed.
Likewise to 5-HTP (Haberzettl et al., 2014), 8-OH-DPAT, buspirone
and TCB-2 were shown to evoke ﬂat body posture, hindlimb abduction,
piloerection and a decrease in rearing (see Table 3). Therefore, these
four responses do not seem to be speciﬁc for 5-HT1A or 5-HT2A receptor
activation. Forepaw treading and hunched back were solely elicited by
5-HTP (Haberzettl et al., 2014), and neither by the two 5-HT1A receptor
agonists nor the5-HT2A receptor agonist, indicating that these responses
aremediated by other 5-HT receptor subtypes (see Table 3). Tremorwas
observed following the administration of 5-HTP (Haberzettl et al., 2014)
and of both 5-HT1A receptor agonists, but not of TCB-2 (Table 3). Hence,
inmice this response can be related to a stimulation of 5-HT1A receptors.
However, there is a study demonstrating paw tremor inmice induced by
DOI, a 5-HT2A/2C receptor agonist. Therefore, it cannot be excluded that
5-HT2A/2C receptors are involved in the induction of tremor. In the pres-
ent study, neither 8-OH-DPAT and buspirone nor TCB-2 evoked back-
ward walking, head shaking and head weaving as well as salivation in
mice. These four responses were also not observed after the administra-
tion of 5-HTP (Haberzettl et al., 2014). Conﬁrming our ﬁndings, none of
these symptoms were consistently and reliably demonstrated after se-
rotonergic treatment in previous studies (Fox et al., 2007; Haberzettl
et al., 2013). Hence, we suggest that these signs are not reliable indica-
tors of the SS in mice. However, it has to be considered that head
twitches, head weaving and head shakes are often not exactly deﬁned
in the publications and ambiguous termsmight have been used. Further
reasons for the different study results might be differences in strains,
drug dosages, and procedural variables.
The incidence of the potentially life-threatening SS is increasing as a
result of approval of novel serotonergic drugs and rising numbers of
prescriptions. However, the risk calculation for the SS in humans is
mostly based on case studies (Gillman, 1999), since toxicity data on se-
rotonergic drugs is not systematically collected (Boyer & Shannon,
133R. Haberzettl et al. / Journal of Pharmacological and Toxicological Methods 70 (2014) 129–1332005; Gillman, 1998). To our knowledge, there is only one study in
healthy human volunteers investigating the toxicity of serotonergic
and 5-HT enhancing drugs (Parks et al., 2012). Thus, animalmodels pro-
vide a good option to assess the risk potential of a drug or a drug com-
bination to induce an SS already at an early stage of drug development.
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